---
schema_version: "secwatch.filing_event.v1"
accession: "0001397702-24-000029"
form_type: "8-K"
ticker: null
cik: "0001397702"
company_name: "Silk Road Medical Inc"
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:14:59.573041+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Silk Road Medical Q1 2024 revenue $48.5M (+21% YoY); net loss narrows to $14.1M

## Summary
- Revenue $48.5M, up 21% YoY driven by increased TCAR adoption.
- Gross margin 75%, up from 69% YoY due to favorable production variances.
- Net loss $14.1M ($0.36/share) vs $16.5M ($0.43/share) in Q1 2023.
- Adjusted EBITDA loss improved to $3.9M from $7.4M in Q1 2023.
- CEO cites commercial progress and steps toward sustainable profitability.

## SEC filing metadata
- accession: 0001397702-24-000029
- form_type: 8-K
- cik: 0001397702
- company_name: Silk Road Medical Inc
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1397702/000139770224000029/0001397702-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1397702/000139770224000029/silk-20240430x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001397702-24-000029
- JSON: https://secwatch.observer/filing/0001397702-24-000029.json
- Plain text: https://secwatch.observer/filing/0001397702-24-000029.txt

## Key facts
- Earnings Releases
  Silk Road Medical Inc reported the three months ended March 31, 2024 results: revenue $48.5 million, EPS $0.36 per share.
  - Period: the three months ended March 31, 2024
  - Revenue: $48.5 million
  - EPS: $0.36 per share
  - Result: preliminary results
  source text: and patients and in our opportunity to drive strong, sustainable growth as a business.”  First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $48.5 million, an increase of $8.4 million or 21%, compared to the first quarter of 2023. Growth was driven primarily by increased TCAR adoption.  Gross profit for the first quarter of 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1397702/000139770224000029/0001397702-24-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.